Department of Urology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands; Department of Urology, Leiden UMC, Leiden, The Netherlands.
Clin Genitourin Cancer. 2023 Jun;21(3):342-348. doi: 10.1016/j.clgc.2023.02.004. Epub 2023 Feb 22.
18F-fluorodeoxyglucose positron-emission tomography-computed tomography (FDG-PET/CT) is increasingly used in the preoperative staging of patients with muscle-invasive bladder cancer. The clinical added value of FDG-PET/CT in high-risk non-muscle invasive bladder cancer (NMIBC) is unknown. In this study, the value of FDG-PET/CT in addition to contrast enhanced (CE)-CT was evaluated in high-risk NMIBC before radical cystectomy (RC).
This is a retrospective analysis of consecutive patients with high risk and very-high risk urothelial NMIBC scheduled for RC in a tertiary referral center between 2011 and 2020. Patients underwent staging with CE-CT (chest and abdomen/pelvis) and FDG-PET/CT. We assessed the clinical disease stage before and after FDG-PET/CT and the treatment recommendation based on the stage before and after FDG-PET/CT. The accuracy of CT and FDG-PET/CT for identifying metastatic disease was defined by the receiver-operating curve using a reference-standard including histopathology/cytology (if available), imaging and follow-up.
A total of 92 patients were identified (median age: 71 years). In 14/92 (15%) patients, FDG-PET/CT detected metastasis (12 suspicious lymph nodes and 4 distant metastases). The disease stage changed in 11/92 (12%) patients based on additional FDG-PET/CT findings. FDG-PET/CT led to a different treatment in 9/92 (10%) patients. According to the reference standard, 25/92 (27%) patients had metastases. The sensitivity, specificity and accuracy of FDG-PET/CT was 36%, 93% and 77% respectively, versus 12%, 97% and 74% of CE-CT only. The area under the ROC curve was 0.643 for FDG-PET/CT and 0.545 for CT, P = .036.
The addition of FDG-PET/CT to CE-CT imaging changed the treatment in 10% of patients and proved to be a valuable diagnostic tool in a selected subgroup of NMIBC patients scheduled for RC.
18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(FDG-PET/CT)在肌层浸润性膀胱癌患者的术前分期中越来越多地被使用。FDG-PET/CT 在高危非肌层浸润性膀胱癌(NMIBC)中的临床附加价值尚不清楚。在这项研究中,评估了 FDG-PET/CT 在高危 NMIBC 患者根治性膀胱切除术(RC)前对比增强(CE)-CT 之外的价值。
这是一项连续回顾性分析,纳入了 2011 年至 2020 年期间在三级转诊中心接受 RC 治疗的高危和极高危尿路上皮 NMIBC 患者。患者接受了 CE-CT(胸部和腹部/骨盆)和 FDG-PET/CT 分期。我们评估了 FDG-PET/CT 前后的临床疾病分期,并根据 FDG-PET/CT 前后的分期推荐治疗建议。CT 和 FDG-PET/CT 对识别转移性疾病的准确性通过使用包括组织病理学/细胞学(如有)、影像学和随访的参考标准的受试者工作特征曲线来定义。
共确定了 92 例患者(中位年龄:71 岁)。在 14/92(15%)例患者中,FDG-PET/CT 检测到转移(12 个可疑淋巴结和 4 个远处转移)。根据额外的 FDG-PET/CT 结果,11/92(12%)例患者的疾病分期发生了变化。根据参考标准,25/92(27%)例患者存在转移。FDG-PET/CT 的敏感性、特异性和准确性分别为 36%、93%和 77%,而仅 CE-CT 为 12%、97%和 74%。FDG-PET/CT 的 ROC 曲线下面积为 0.643,CT 为 0.545,P=0.036。
FDG-PET/CT 与 CE-CT 成像联合应用改变了 10%患者的治疗方法,并在接受 RC 治疗的选定高危 NMIBC 患者亚组中证明是一种有价值的诊断工具。